To the Editor: In his Editorial about the null results of the SELECT and Physicians' Health Study II clinical trials, Dr Gann1 raised the important issue of preclinical science in chemopreventive agent development. A critical component of the preclinical development of any candidate cancer chemopreventive agent is the demonstration of its anticarcinogenic efficacy in biologically relevant animal models. Findings of significant chemopreventive activity in such models are key elements of the rational selection of agents for subsequent evaluation in clinical prevention trials.
Bosland MC, McCormick DL. Antioxidant Supplementation and Cancer Prevention. JAMA. 2009;301(18):1877-1879. doi:10.1001/jama.2009.628